A recently published study highlighted the strong performance of the Insulet (Nasdaq:PODD) Omnipod 5 in children and young ...

RBC Capital analyst Shagun Singh initiated coverage of Insulet (PODD) with an Outperform rating and $340 price target The firm says Insulet ...

Until Insulet's Omnipod came on the market at the end of 2005, all insulin pumps consisted of a controller and insulin reservoir attached to the injection site by a long flexible tube. The Omnipod ...

Tandem is following competitor Insulet’s lead with the second automated insulin delivery system indicated for Type 2 diabetes ...

Insulet develops, manufactures, and markets the Omnipod Insulin Management System for people that have diabetes. This system is worn on the body for approximately three days at a time and allows ...

Valued at $19.8 billion by market cap, the company develops, manufactures, and sells insulin ... Omnipod 5, both in the U.S. and globally. The company also saw increasing sales in drug delivery ...

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin ...

Morningstar analyst Debbie Wang, in a February 26 note, said Insulet's Omnipod system "is inconspicuous and easy to use and has so far been very successful among patients new to insulin pumps. These ...

The producer of the Omnipod Insulin Management System ... in the sector at large, including Insulet. Beta is also innovating in the space, by providing pumps which use adaptive and closed-loop ...

Bengaluru: Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps. The company produces and sells Omnipod ...

A Closer Look Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of ...

Insulet’s Q4 revenue hit $597.5 million, up 17.2%, beating the $582.81 million consensus. Omnipod revenue climbed ... The automated insulin delivery technology maker reported sales of $597.5 ...